Dr. Eric C. Santos, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 312
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301100032
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Spectrum Health Grand Rapids, MI
- Mercy Health Saint Mary's Grand Rapids, MI
- Spectrum Health United Hospital Greenville, MI
- Corewell Health Big Rapids Hospital Big Rapids, MI
- Corewell Health Pennock Hospital Hastings, MI
Medical groups
- Cancer and Hematology Centers of Western Mi, P.c. (110 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 312
- Services billed
- 104,743
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 8,550 | 20 |
| Injection, lanreotide, 1 mg | 7,080 | 14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,856 | 45 |
| Injection, palonosetron hcl, 25 mcg | 1,150 | 34 |
| Injection, fluorouracil, 500 mg | 709 | 14 |
| Injection of additional new drug or substance into vein | 355 | 52 |
| Injection, potassium chloride, per 2 meq | 325 | 13 |
| Insertion of needle into vein for collection of blood sample | 314 | 57 |
| Administration of chemotherapy into vein, 1 hour or less | 296 | 72 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 287 | 53 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Grand Rapids, MI | 112 |
| Tagrisso (osimertinib mesylate) | 79 |
| Folic Acid Other prescribers in Grand Rapids, MI | 59 |
| Olanzapine Other prescribers in Grand Rapids, MI | 55 |
| Xarelto (rivaroxaban) Other prescribers in Grand Rapids, MI | 46 |
| Dexamethasone Other prescribers in Grand Rapids, MI | 38 |
| Prednisone Other prescribers in Grand Rapids, MI | 30 |
| Eliquis (apixaban) Other prescribers in Grand Rapids, MI | 29 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Grand Rapids, MI | 27 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Grand Rapids, MI | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 24 payments worth $566 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $139 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $71.01 |
| Merck Sharp & Dohme LLC | $68.90 |
| Novartis Pharmaceuticals Corporation | $65.69 |
| Eli Lilly and Company | $57.83 |
| Genzyme Corporation | $38.19 |
| Daiichi Sankyo Inc. | $25.09 |
| Kite Pharma, Inc. | $24.64 |
| Food and Beverage | $566 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $1,056,665 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvaluma…
Amgen Inc. - A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company · Recruiting · NCT06119581 - A phase iii, randomized, open-label, multicenter study evaluating the efficacy and safety of divaras
Genentech, Inc. - A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (…
Amgen Inc. - A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adeno…
AstraZeneca Pharmaceuticals LP - A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.